- Test Name
- Goodpasture and Vasculitis Disease Screening Panel
- Aliases
- GVDS panel, GBM autoantibody, PR3 autoantibody, MPO autoantibody. ANCA and Glomerular Basement Membrane Diseases.
- Provincial Mnemonic
- VASCUP
- LOINC Test Code
- Description and Primary Use
- Since Goodpasture’s disease and ANCA Associated Vasculitis (AAV) may have the same clinical presentation, it is recommended that GBM and ANCA (MPO and PR3) autoantibodies should be analyzed in parallel in patients with renal disease. This screening approach is provided through the new GVDS test panel. Any positive test result on the GVDS test panel will be reported and reflexively referred out for quantitative measurement of GBM, MPO or PR3 autoantibody testing. The diagnosis of Goodpasture’s disease relies on the detection of GBM autoantibodies in tissues or circulation in combination with the detection of glomerulonephritis and/or alveolitis. GBM autoantibodies are highly specific and sensitive markers of the disease and are by definition present in all patients with Goodpasture’s disease. Clinical progression of the disease correlates with antibody concentrations, with high concentrations of circulating GBM autoantibodies indicating an unfavorable prognosis. ANCA targeting proteinase 3 (PR3) and myeloperoxidase (MPO) expressed by innate immune cells are salient diagnostic and pathogenic features of small vessel vasculitis. MPO and PR3 autoantibodies testing (GVDS test) should be ordered for patient with at least one of the following clinical signs or symptoms: glomerulonephritis, pulmonary hemorrhage, cutaneous vasculitis with systemic features, multiple lung nodules, chronic destructive disease of the upper airways, long-standing sinusitis or otitis, subglottic tracheal stenoses, mononeuritis multiplex or other peripheral neuropathy, retro-orbital mass or scleritis. Revised consensus on the use of ANCA testing now recommends high-quality immunoassays as primary screening method and to reflex positive sample for a second analysis using a different immunoassay methodology. We provide this through the reflexive testing strategy described above.
- Reorder interval
- 30 Days
- TAT
- 14 Days; max delay 31 Days
- Test Cost
- Not Available
- Tier
- 1 - General Availability
- Ordering Requirements (Restrictions / Conditions)
No Restrictions
- Required Consultations
- None
- Algorithms and Guidelines
- Special Patient Preparation
None
- Special Collection / Transport / Processing Requirements
- Criteria for Rejection
Please consult specimen stability guide
- Laboratory Service Area
- Clinical Chemistry
- Performing Laboratory / Site
- Category 4 Laboratory (HSC only)
- Last Updated
- 21-Feb-20